Ep 31 Talking About Glaucoma - 6Jun2019 LEWIS Rick Rho Kinase Inhibitors: a new class of drugs (AAC)
/[This is the AAC version. Starting with Episode 30, aside from minor sound quality differences, there is no longer a difference between the AAC and MP3 versions of my podcast. The additional artwork and chapter markers have been too time consuming and have not really been noticed by anyone! Enjoy the show.]
Richard A. Lewis, MD
The goal of the late Dave Epstein was to find a drug that treats the cause of glaucoma by improving trabecular meshwork outflow. After many years of research, Aerie Pharmaceuticals was formed and refined a Rho Kinase inhibitor called Netarsudil. In April 2018 this came to market as Rhopressa and March 2019, combined with latanoprost, as Roclatan. Today I’m talking with Rick Lewis, a glaucoma colleague based in Sacramento and Chief Medical Officer for Aerie Pharmaceuticals…and we’re Talking About Glaucoma.
Talking About Glaucoma is a podcast of indeterminate frequency and duration. It’s available for free on Apple Podcasts, Google Podcasts, PocketCasts, and many other podcast services. Please rate the podcast on Apple Podcasts and tell your friends about it, so that it can reach more listeners. Drop me a line at podcast@iguy.org with your show ideas.
—————————————————————————
Selected links:
https://aeriepharma.com/
https://clinicaltrials.gov/ct2/show/NCT02246764
—————————————————————————
Production information:
This episode was recorded March 2019 during the Annual Meeting of the American Glaucoma Society in San Francisco using two Shure SM58 microphones with a Marantz PMD661 digital recorder. Mixing and sound levelling were completed June 2019 on an iMac using Hindenberg Journalist Pro software. Narration was overdubbed using a Blue Yeti Microphone.
Opinions expressed in this podcast are those of the speakers and are not intended to be taken as the standard of care for glaucoma treatment. Please always weigh the complete clinical picture and involve patients with any decisions in their care.
Robert M Schertzer, MD, MEd, FRCSC
podcast@iguy.org
Twitter - http://twitter.com/robschertzer
or http://iguy.tv/twitter
Blog - http://wholelottarob.com
or http://iguy.tv/blog
Facebook - http://facebook.com/talkingaboutglaucoma
Office website - http://westcoastglaucoma.com
or http://iguy.tv/office
Theme music “Middle East Gold” ©Daniel Schertzer 2010 and published by Les Prods DOSWA Enr
© 2019 DOSWA Prods Enr/Robert M Schertzer MD. MEd, FRCSC
—————————————————————————
Today’s guest:
Richard A. Lewis, MD
Sacramento Eye Consultants
1515 River Park Drive, Suite 100, Sacramento, CA 95815
Tel: 1-916-649-1515
rlewiseyemd@yahoo.com
https://www.sacramentoeyeconsultants.com/sacramento/our-doctors/richard-a-lewis-md.htm
—————————————————————————
iTunes Subtitle:
A talk with Rick Lewis, a glaucoma colleague based in Sacramento and Chief Medical Officer for Aerie Pharmaceuticals about a new class of glaucoma drugs called Rho Kinase inhibitors that came to market as Netasurdil or Rhopressa.
iTunes Summary:
The goal of the late Dave Epstein was to find a drug that treats the cause of glaucoma by improving trabecular meshwork outflow. After many years of trying, Aerie Pharmaceuticals was formed and refined a Rho Kinase inhibitor called Netarsudil. In April 2018 this came to market as Rhopressa and March 2019, combined with latanoprost, as Roclatan. Today I’m talking with Rick Lewis, a glaucoma colleague based in Sacramento and Chief Medical Officer for Aerie Pharmaceuticals.